Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial (vol 157, pg 1279, 2021)

被引：0
|
作者：
Terlizzi, Joseph P. [1 ]
Baker, Jonathan [1 ]
Goldstone, Stephen E. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Surg, 420 W 23rd St,Ste PB, New York, NY 10011 USA
来源：
JAMA DERMATOLOGY | 2021年 / 157卷 / 11期
关键词：
D O I：
10.1001/jamadermatol.2021.4442
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：1384 / 1384
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial
    Glatt, Sophie
    Jemec, Gregor B. E.
    Forman, Seth
    Sayed, Christopher
    Schmieder, George
    Weisman, Jamie
    Rolleri, Robert
    Seegobin, Seth
    Baeten, Dominique
    Ionescu, Lucian
    Zouboulis, Christos C.
    Shaw, Stevan
    [J]. JAMA DERMATOLOGY, 2021, 157 (11) : 1279 - 1288
  • [2] A double-blind, placebo-controlled, crossover trial to assess the efficacy and safety of infliximab for patients with moderate to severe hidradenitis suppurativa
    Grant, Annika
    Gonzalez, T.
    Kerdel, E. A.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB38 - AB38
  • [3] Infliximab therapy for patients with moderate to severe hidradenitis, suppurativa: A randomized, double-blind, placebo-controlled crossover trial
    Grant, Annika
    Gonzalez, Tayler
    Montgomery, Michael O.
    Cardenas, Vanessa
    Kerdel, Francisco A.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (02) : 205 - 217
  • [4] Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY):a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (vol 397, pg 475, 2021)
    Gordon, K. B.
    Foley, P.
    Krueger, J. G.
    [J]. LANCET, 2021, 397 (10280): : 1182 - 1182
  • [5] Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: Results from the placebo-controlled portion of a phase II, randomized, double-blind study
    Kimball, A.
    Jemec, G.
    Okun, M.
    Gu, Y.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB155 - AB155
  • [6] Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: results from the placebo-controlled portion of a phase II, randomized, double-blind study
    Kimball, A. B.
    Jemec, G.
    Gu, Y.
    Okun, M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 : 6 - 6
  • [7] A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa
    Miller, I.
    Lynggaard, C. D.
    Lophaven, S.
    Zachariae, C.
    Dufour, D. N.
    Jemec, G. B. E.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (02) : 391 - 398
  • [8] Efficacy and Safety of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Study
    Kimball, Alexa B.
    Ackerman, Lindsay
    Schlosser, Bethanee J.
    Prajapati, Vimal H.
    Fretzin, Scott
    Takahashi, Hidetoshi
    Zhan, Tianyu
    Huang, Xiaohong
    Camp, Heidi S.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB42 - AB42
  • [9] Efficacy and safety of adalimumab treatment in women with moderate to severe hidradenitis suppurativa: Analysis from the placebo-controlled portion of a phase II, randomized, double-blind study
    Gottlieb, Alice B.
    Menter, Alan
    Teixeira, Henrique D.
    Belknap, Kimberly R.
    Gu, Yihua
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB49 - AB49
  • [10] Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety
    Lai, Vivien Wai Yun
    Chen, Gang
    Gin, Douglas
    Sinclair, Rodney
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (03) : 694 - 701
12345